glp-1 receptor agonist patient assistance programs MCT2D GLP-1 Receptor Agonist Market Size

An evolving body of evidence shows that weight reduction improves health outcomes beyond its effect on intermediary CVD risk factors

In SURPASS-AP trial insulin-naive diabetic patients not adequately controlled on therapy with metformin (with or without a sulphonylurea) in Australia, India, China and South Korea, were randomized to TZP 5 mg, 10 mg or 15 mg or insulin glargine

GLP-1 drugs: Medicare coverage and policy considerations (CRS In Focus IF12758)

S., Francis J

doi: 10.1007/s40120-022-00350-y 34 BarbierPZejneliOMartinhoMLasorsaABelleVSmet-NoccaCet al

Semaglutide was associated with a reduced risk for worsening depression, anxiety, and substance use disorder (adjusted hazard ratios, 0.56, 0.62, and 0.53, respectively), while liraglutide was only associated with a reduced risk for worsening depression (adjusted hazard ratio, 0.74)